Department of Obstetrics and Gynecology and Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA.
BJOG. 2017 Jun;124(7):1028-1037. doi: 10.1111/1471-0528.14579. Epub 2017 Apr 1.
Uterine leiomyosarcoma (LMS) are rare but aggressive tumours with poor clinical outcomes regardless of stage. Most tumours are identified by histopathology at time of surgery, and pre-operative diagnosis remains a clinical challenge. Management of early-stage LMS relies on surgical resection. Cytotoxic chemotherapy remains the mainstay of therapy for advanced-stage, recurrent or metastatic LMS, and includes single or combination doxorubicin-, ifosfamide- or gemcitabine-based regimens. Recent interest in genetic biomarkers led to developments of targeted therapies for LMS, although more research is needed to understand the molecular complexities underlying LMS to guide the development of novel treatment strategies.
The diagnosis and treatment of uterine LMS is challenging. Novel biomarkers offer hope for future therapies.
子宫平滑肌肉瘤（LMS）是罕见但侵袭性的肿瘤，无论分期如何，临床结局均较差。大多数肿瘤在手术时通过组织病理学来确定，术前诊断仍然是一个临床挑战。早期 LMS 的治疗依赖于手术切除。细胞毒性化疗仍然是晚期、复发性或转移性 LMS 的主要治疗方法，包括单药或联合多柔比星、异环磷酰胺或吉西他滨的方案。最近对遗传生物标志物的关注导致了针对 LMS 的靶向治疗的发展，尽管需要更多的研究来了解 LMS 的分子复杂性，以指导新的治疗策略的制定。
子宫 LMS 的诊断和治疗具有挑战性。新型生物标志物为未来的治疗方法带来希望。
Zotero 插件